AIM ImmunoTech Inc. (AIM)
USD 0.2
(-6.89%)
USD 0.2
(-6.89%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.94 Million USD | 81.99% |
| 2022 | -26.21 Million USD | 17.93% |
| 2021 | -31.94 Million USD | 11.8% |
| 2020 | -36.21 Million USD | -837.6% |
| 2019 | 4.91 Million USD | -12.73% |
| 2018 | 5.62 Million USD | 1230.02% |
| 2017 | 423 Thousand USD | 117.57% |
| 2016 | -2.4 Million USD | -13.91% |
| 2015 | -2.11 Million USD | 0.94% |
| 2014 | -2.13 Million USD | -185.68% |
| 2013 | -747 Thousand USD | 64.61% |
| 2012 | -2.11 Million USD | -139.89% |
| 2011 | -880 Thousand USD | 68.15% |
| 2010 | -2.76 Million USD | 95.24% |
| 2009 | -58.07 Million USD | -849.04% |
| 2008 | -6.11 Million USD | 46.66% |
| 2007 | -11.47 Million USD | -5198.22% |
| 2006 | 225 Thousand USD | 136.89% |
| 2005 | -610 Thousand USD | 88.4% |
| 2004 | -5.26 Million USD | -208.32% |
| 2003 | -1.7 Million USD | 24.38% |
| 2002 | -2.25 Million USD | 27.39% |
| 2001 | -3.1 Million USD | 16.5% |
| 2000 | -3.72 Million USD | 41.86% |
| 1999 | -6.4 Million USD | 46.67% |
| 1998 | -12 Million USD | -33.33% |
| 1997 | -9 Million USD | -69.81% |
| 1996 | -5.3 Million USD | 17.19% |
| 1995 | -6.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 55 Thousand USD | 101.17% |
| 2024 Q2 | -195 Thousand USD | -454.55% |
| 2023 Q3 | -14.51 Million USD | 28.27% |
| 2023 FY | -4.72 Million USD | 81.99% |
| 2023 Q4 | -4.72 Million USD | 67.47% |
| 2023 Q2 | -20.23 Million USD | 10.39% |
| 2023 Q1 | -22.58 Million USD | 13.87% |
| 2022 Q1 | -28.84 Million USD | 9.7% |
| 2022 FY | -26.21 Million USD | 17.93% |
| 2022 Q4 | -26.21 Million USD | 9.27% |
| 2022 Q3 | -28.89 Million USD | 13.91% |
| 2022 Q2 | -33.56 Million USD | -16.36% |
| 2021 Q3 | -37.2 Million USD | 9.22% |
| 2021 FY | -31.94 Million USD | 11.8% |
| 2021 Q4 | -31.94 Million USD | 14.14% |
| 2021 Q1 | -46.55 Million USD | -28.55% |
| 2021 Q2 | -40.98 Million USD | 11.96% |
| 2020 Q3 | -36.14 Million USD | -14.52% |
| 2020 Q4 | -36.21 Million USD | -0.19% |
| 2020 FY | -36.21 Million USD | -837.6% |
| 2020 Q1 | -20.98 Million USD | -527.37% |
| 2020 Q2 | -31.56 Million USD | -50.42% |
| 2019 Q4 | 4.91 Million USD | 281.52% |
| 2019 FY | 4.91 Million USD | -12.73% |
| 2019 Q2 | 3.92 Million USD | 0.82% |
| 2019 Q3 | -2.7 Million USD | -168.86% |
| 2019 Q1 | 3.89 Million USD | -30.75% |
| 2018 Q3 | 1.89 Million USD | 298.54% |
| 2018 FY | 5.62 Million USD | 1230.02% |
| 2018 Q4 | 5.62 Million USD | 196.42% |
| 2018 Q2 | -956 Thousand USD | 26.23% |
| 2018 Q1 | -1.29 Million USD | -406.38% |
| 2017 Q1 | -776 Thousand USD | 67.77% |
| 2017 FY | 423 Thousand USD | 117.57% |
| 2017 Q4 | 423 Thousand USD | -56.07% |
| 2017 Q3 | 963 Thousand USD | 236.6% |
| 2017 Q2 | -705 Thousand USD | 9.15% |
| 2016 Q2 | -1.53 Million USD | -51.83% |
| 2016 Q4 | -2.4 Million USD | 46.17% |
| 2016 Q1 | -1.01 Million USD | 52.08% |
| 2016 Q3 | -4.47 Million USD | -190.83% |
| 2016 FY | -2.4 Million USD | -13.91% |
| 2015 Q1 | -2.92 Million USD | -37.16% |
| 2015 Q2 | -1.83 Million USD | 37.31% |
| 2015 Q3 | -1.15 Million USD | 36.89% |
| 2015 FY | -2.11 Million USD | 0.94% |
| 2015 Q4 | -2.11 Million USD | -82.56% |
| 2014 FY | -2.13 Million USD | -185.68% |
| 2014 Q1 | -4.04 Million USD | -441.5% |
| 2014 Q3 | -1.23 Million USD | 52.07% |
| 2014 Q4 | -2.13 Million USD | -73.5% |
| 2014 Q2 | -2.56 Million USD | 36.56% |
| 2013 Q3 | 5.58 Million USD | -5.69% |
| 2013 Q4 | -747 Thousand USD | -113.38% |
| 2013 Q1 | 5.75 Million USD | 372.71% |
| 2013 Q2 | 5.92 Million USD | 2.85% |
| 2013 FY | -747 Thousand USD | 64.61% |
| 2012 Q2 | 2.28 Million USD | 284.81% |
| 2012 Q3 | 2.71 Million USD | 18.71% |
| 2012 FY | -2.11 Million USD | -139.89% |
| 2012 Q4 | -2.11 Million USD | -177.72% |
| 2012 Q1 | -1.23 Million USD | -40.68% |
| 2011 Q1 | -2.76 Million USD | 0.0% |
| 2011 FY | -880 Thousand USD | 68.15% |
| 2011 Q3 | -3.85 Million USD | -103.65% |
| 2011 Q2 | -1.89 Million USD | 31.52% |
| 2011 Q4 | -880 Thousand USD | 77.16% |
| 2010 Q1 | -50.65 Million USD | 12.77% |
| 2010 Q2 | -5.27 Million USD | 89.59% |
| 2010 Q4 | -2.76 Million USD | 3.76% |
| 2010 FY | -2.76 Million USD | 95.24% |
| 2010 Q3 | -2.87 Million USD | 45.57% |
| 2009 FY | -58.07 Million USD | -849.04% |
| 2009 Q1 | -3.62 Million USD | 40.82% |
| 2009 Q2 | -40.65 Million USD | -1022.81% |
| 2009 Q3 | -61.04 Million USD | -50.14% |
| 2009 Q4 | -58.07 Million USD | 4.87% |
| 2008 Q2 | -10.14 Million USD | -5.16% |
| 2008 FY | -6.11 Million USD | 46.66% |
| 2008 Q3 | -7.59 Million USD | 25.14% |
| 2008 Q4 | -6.11 Million USD | 19.4% |
| 2008 Q1 | -9.64 Million USD | 15.93% |
| 2007 FY | -11.47 Million USD | -5198.22% |
| 2007 Q4 | -11.47 Million USD | -74.76% |
| 2007 Q3 | -6.56 Million USD | 6.08% |
| 2007 Q1 | -192 Thousand USD | -185.33% |
| 2007 Q2 | -6.98 Million USD | -3540.1% |
| 2006 FY | 225 Thousand USD | 136.89% |
| 2006 Q1 | -6.99 Million USD | -1046.72% |
| 2006 Q4 | 225 Thousand USD | 129.53% |
| 2006 Q2 | 1.08 Million USD | 115.51% |
| 2006 Q3 | -762 Thousand USD | -170.23% |
| 2005 Q2 | -1.15 Million USD | 53.52% |
| 2005 FY | -610 Thousand USD | 88.4% |
| 2005 Q1 | -2.47 Million USD | 52.97% |
| 2005 Q4 | -610 Thousand USD | -2340.0% |
| 2005 Q3 | -25 Thousand USD | 97.83% |
| 2004 Q1 | -663 Thousand USD | 61.14% |
| 2004 Q4 | -5.26 Million USD | 47.13% |
| 2004 Q3 | -9.94 Million USD | -677.8% |
| 2004 Q2 | -1.27 Million USD | -92.91% |
| 2004 FY | -5.26 Million USD | -208.32% |
| 2003 Q4 | -1.7 Million USD | 54.42% |
| 2003 Q3 | -3.74 Million USD | 19.66% |
| 2003 FY | -1.7 Million USD | 24.38% |
| 2003 Q1 | -2.2 Million USD | 2.44% |
| 2003 Q2 | -4.65 Million USD | -111.68% |
| 2002 Q2 | -3.29 Million USD | 5.04% |
| 2002 Q3 | -3.47 Million USD | -5.25% |
| 2002 Q4 | -2.25 Million USD | 35.0% |
| 2002 FY | -2.25 Million USD | 27.39% |
| 2002 Q1 | -3.47 Million USD | -11.78% |
| 2001 Q3 | -2.85 Million USD | -10.6% |
| 2001 Q1 | -2.05 Million USD | 44.72% |
| 2001 Q2 | -2.58 Million USD | -25.67% |
| 2001 Q4 | -3.1 Million USD | -8.67% |
| 2001 FY | -3.1 Million USD | 16.5% |
| 2000 Q4 | -3.72 Million USD | 46.07% |
| 2000 Q2 | -8.24 Million USD | 16.61% |
| 2000 Q3 | -6.89 Million USD | 16.37% |
| 2000 FY | -3.72 Million USD | 41.86% |
| 2000 Q1 | -9.89 Million USD | -54.58% |
| 1999 Q2 | -9.1 Million USD | 13.33% |
| 1999 Q3 | -6.8 Million USD | 25.27% |
| 1999 Q4 | -6.4 Million USD | 5.88% |
| 1999 FY | -6.4 Million USD | 46.67% |
| 1999 Q1 | -10.5 Million USD | 12.5% |
| 1998 Q4 | -12 Million USD | 16.08% |
| 1998 Q2 | -6.6 Million USD | 14.29% |
| 1998 Q1 | -7.7 Million USD | 14.44% |
| 1998 Q3 | -14.3 Million USD | -116.67% |
| 1998 FY | -12 Million USD | -33.33% |
| 1997 Q2 | -2.8 Million USD | 30.0% |
| 1997 Q1 | -4 Million USD | 24.53% |
| 1997 Q3 | -1.8 Million USD | 35.71% |
| 1997 Q4 | -9 Million USD | -400.0% |
| 1997 FY | -9 Million USD | -69.81% |
| 1996 FY | -5.3 Million USD | 17.19% |
| 1996 Q2 | -2.5 Million USD | 30.56% |
| 1996 Q1 | -3.6 Million USD | 43.75% |
| 1996 Q4 | -5.3 Million USD | 19.7% |
| 1996 Q3 | -6.6 Million USD | -164.0% |
| 1995 Q4 | -6.4 Million USD | 0.0% |
| 1995 FY | -6.4 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | -29.594% |
| Armata Pharmaceuticals, Inc. | 106.84 Million USD | 104.627% |
| Actinium Pharmaceuticals, Inc. | -74.56 Million USD | 93.369% |
| Azitra, Inc. | -910.04 Thousand USD | -443.272% |
| Can-Fite BioPharma Ltd. | -4.23 Million USD | -16.659% |
| Chromocell Therapeutics Corporation | 1.17 Million USD | 521.737% |
| Calidi Biotherapeutics, Inc. | 5.18 Million USD | 195.315% |
| CEL-SCI Corporation | 9.42 Million USD | 152.451% |
| iBio, Inc. | -9.75 Million USD | 49.292% |
| Lineage Cell Therapeutics, Inc. | -32.49 Million USD | 84.783% |
| MAIA Biotechnology, Inc. | -7.15 Million USD | 30.86% |
| Matinas BioPharma Holdings, Inc. | -1.28 Million USD | -285.948% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | 1227.624% |
| NovaBay Pharmaceuticals, Inc. | -390 Thousand USD | -1167.692% |
| NanoViricides, Inc. | -4.79 Million USD | -3.048% |
| Oragenics, Inc. | -3.17 Million USD | -55.923% |
| BiomX Inc. | -772 Thousand USD | -540.415% |
| BiomX Inc. | -772 Thousand USD | -540.415% |
| Protalix BioTherapeutics, Inc. | 2.64 Million USD | 286.777% |
| Palatin Technologies, Inc. | -8.93 Million USD | 44.68% |
| Scorpius Holdings, Inc. | 13.85 Million USD | 135.678% |